ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2023-3-390-397ophthalmology-2162Research ArticleОБЗОРЫREVIEWSГипромеллоза: место в офтальмологической практикеHypromellose in Ophthalmologyhttps://orcid.org/0000-0001-7729-2169БутрановаО. И.ButranovaO. I.

Бутранова Ольга Игоревна, кандидат медицинских наук, доцент кафедры общей и клинической фармакологии

ул. Миклухо-Маклая, 6, Москва, 117198

Butranova Olga I., PhD, Associate Professor, Department of general and clinical pharmacology

Miklukho-Maklaya str., 6, Moscow, 117198

https://orcid.org/0000-0002-6348-6867ЗыряновС. К.ZyryanovS. K.

Зырянов Сергей Кенсаринович, доктор медицинских наук профессор, заведующий кафедрой общей и клинической фармакологии; заместитель главного врача

ул. Миклухо-Маклая, 6, Москва, 117198

ул. Писцовая, 10, Москва, 127015

Zyryanov Sergey K., MD, Professor, head of the Department of general and clinical pharmacology; Deputy chief physician

Miklukho-Maklaya str., 6, Moscow, 117198

Pistsovaya str., 10, Moscow, 127015

ФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияPeoples’ Friendship University of Russia named after Patrice LumumbaRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»; ГБУЗ «Городская клиническая больница № 24 Департамента здравоохранения города Москвы»РоссияPeoples’ Friendship University of Russia named after Patrice Lumumba; City Clinical Hospital No. 24Russian Federation202330092023203390397Copyright © Бутранова О.И., Зырянов С.К., 20232023Бутранова О.И., Зырянов С.К.Butranova O.I., Zyryanov S.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/2162

Местные лекарственные формы — основы ведения пациентов в офтальмологической практике. Глаз является структурой, эволюционно защищенной от воздействия ксенобиотиков рядом физиологических и анатомических барьеров. Разработка лекарственных форм, таргетная доставка которых в структуры глаза осуществляется благодаря включению специальных вспомогательных веществ, направлена на повышение эффективности ведения пациентов с глазными болезнями. Механизмы действия, характерные для наиболее распространенных групп вспомогательных веществ, использующихся в офтальмологической практике, лежат в основе их эффективности и безопасности, а также в основе возможности создания различных лекарственных форм. Производные целлюлозы благодаря их физико-химическим и фармакологическим характеристикам являются одной из предпочтительных групп для разработки местных лекарственных форм, применяющихся в офтальмологии. Гипромеллоза (гидроксипропилметилцеллюлоза) — одно из наиболее изученных производных целлюллозы, для которого характерно наличие широкого круга показаний как для действующего (компонент искусственной слезы), так и для вспомогательного вещества. Выгодные фармакологические свойства гипромеллозы (способность обеспечивать длительное воздействие эффективных концентраций препаратов, применяемых местно в офтальмологии, значимо повышать степень гидратации роговицы) приводят к активному изучению данного вещества для оценки возможностей его применения в разработке новых лекарственных форм (наночастицы), а также расширения существующего перечня показаний для применения. Данный обзор посвящен анализу клинических и экспериментальных исследований эффективности и безопасности гипромеллозы.

Dosage forms for topical ocular administration are the basis of patient management in ophthalmology. The eye is a structure evolutionarily protected from the effects of xenobiotics by a number of physiological and anatomical barriers. The development of dosage forms, the targeted delivery into the eye structures is carried out due to the inclusion of special excipients, is aimed at improving the efficiency of managing patients with eye diseases. The action mechanisms of the most common groups of excipients used in ophthalmology underlie their effectiveness and safety, as well as create a basis for the various dosage forms development. Cellulose derivatives, due to their physicochemical and pharmacological characteristics, are one of the preferred groups for the development of topical dosage forms used in ophthalmology. Hypromellose (hydroxypropyl methylcellulose) is one of the most studied cellulose derivatives, which is characterized by a wide range of indications for both the active substance (artificial tear component) and the excipient. The favorable pharmacological properties of hypromellose (the ability to provide long-term exposure to effective concentrations of drugs used topically in ophthalmology, the ability to increase the degree of hydration of the cornea) contribute to the active study of this substance to assess the possibilities of its use in the development of new dosage forms (nanoparticles), as well as expanding the existing list of indications. This review is devoted to the analysis of clinical and experimental studies of the efficacy and safety of hypromellose.

гипромеллозасиндром сухого глазапроизводные целлюлозыфакоэмульсификацияместные лекарственные формы в офтальмологииhypromellosedry eye syndromecellulose derivativesphacoemulsificationdosage forms for topical ocular administrationReferencesTomkins-Netzer O., Lightman S.L., Burke A.E., Sugar E.A., Lim L.L., Jaffe G.J., Altaweel M.M., Kempen J.H., Holbrook J.T., Jabs D.A. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021;128:719–728. doi: 10.1016/j.ophtha.2020.08.035.Tomkins-Netzer O., Lightman S.L., Burke A.E., Sugar E.A., Lim L.L., Jaffe G.J., Altaweel M.M., Kempen J.H., Holbrook J.T., Jabs D.A. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results. Ophthalmology. 2021;128:719–728. doi: 10.1016/j.ophtha.2020.08.035.Conrady CD, Yeh S. A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future. Pharmaceutics. 2021;13(8):1224. Published 2021 Aug 8. doi: 10.3390/pharmaceutics13081224.Conrady CD, Yeh S. A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future. Pharmaceutics. 2021;13(8):1224. Published 2021 Aug 8. doi: 10.3390/pharmaceutics13081224.Mazet R, Yaméogo JBG, Wouessidjewe D, Choisnard L, Gèze A. Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation. Pharmaceutics. 2020;12(6):570. Published 2020 Jun 19. doi: 10.3390/pharmaceutics12060570.Mazet R, Yaméogo JBG, Wouessidjewe D, Choisnard L, Gèze A. Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation. Pharmaceutics. 2020;12(6):570. Published 2020 Jun 19. doi: 10.3390/pharmaceutics12060570.Järvinen T., Järvinen K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 1996;19:203–224. doi: 10.1016/0169-409X(95)00107-I.Järvinen T., Järvinen K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 1996;19:203–224. doi: 10.1016/0169-409X(95)00107-I.Gupta B, Mishra V, Gharat S, Momin M, Omri A. Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems. Pharmaceuticals (Basel). 2021;14(11):1201. Published 2021 Nov 22. doi: 10.3390/ph14111201.Gupta B, Mishra V, Gharat S, Momin M, Omri A. Cellulosic Polymers for Enhanc ing Drug Bioavailability in Ocular Drug Delivery Systems. Pharmaceuticals (Basel). 2021;14(11):1201. Published 2021 Nov 22. doi: 10.3390/ph14111201.Diwan P, Jangde R, Khunte S, Bhardwaj H, K. Suresh P. Ocular Drug Delivery System: Barrier for Drug Permeation, Method to Overcome Barrier [Internet]. Drug Development Life Cycle. IntechOpen; 2022. Available from: http://dx.doi.org/10.5772/intechopen.105401Diwan P, Jangde R, Khunte S, Bhardwaj H, K. Suresh P. Ocular Drug Delivery System: Barrier for Drug Permeation, Method to Overcome Barrier [Internet]. Drug Development Life Cycle. IntechOpen; 2022. Available from: http://dx.doi. org/10.5772/intechopen.105401Kuepfer L, Fuellen G, Stahnke T. Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):288–299. doi: 10.1002/psp4.12918.Kuepfer L, Fuellen G, Stahnke T. Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):288–299. doi: 10.1002/psp4.12918.Mehuys E, Delaey C, Christiaens T, Van Bortel L, Van Tongelen I, Remon JP, Boussery K. Eye drop technique and patient-reported problems in a real-world population of eye drop users. Eye (Lond). 2020 Aug;34(8):1392-1398. doi: 10.1038/ s41433-019-0665-y.Mehuys E, Delaey C, Christiaens T, Van Bortel L, Van Tongelen I, Remon JP, Boussery K. Eye drop technique and patient-reported problems in a real-world population of eye drop users. Eye (Lond). 2020 Aug;34(8):1392-1398. doi: 10.1038/ s41433-019-0665-y.Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, On Behalf Of The Japan Dry Eye Society. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J Clin Med. 2022;11(2):367. Published 2022 Jan 12. doi: 10.3390/jcm11020367.Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, On Behalf Of The Japan Dry Eye Society. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J Clin Med. 2022;11(2):367. Published 2022 Jan 12. doi: 10.3390/jcm11020367.Agarwal P, Craig JP, Rupenthal ID. Formulation Considerations for the Management of Dry Eye Disease. Pharmaceutics. 2021 Feb 3;13(2):207. doi: 10.3390/pharmaceutics13020207.Agarwal P, Craig JP, Rupenthal ID. Formulation Considerations for the Management of Dry Eye Disease. Pharmaceutics. 2021 Feb 3;13(2):207. doi: 10.3390/pharmaceutics13020207.Obert E, Strauss R, Brandon C, Grek C, Ghatnekar G, Gourdie R, Rohrer B. Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology. J Mol Med (Berl). 2017 May;95(5):535-552. doi: 10.1007/s00109-017-1506-8.Obert E, Strauss R, Brandon C, Grek C, Ghatnekar G, Gourdie R, Rohrer B. Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology. J Mol Med (Berl). 2017 May;95(5):535-552. doi: 10.1007/s00109-017-1506-8.Gause S, Hsu KH, Shafor C, Dixon P, Powell KC, Chauhan A. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. Adv Colloid Interface Sci. 2016 Jul;233:139–154. doi: 10.1016/j.cis.2015.08.002.Gause S, Hsu KH, Shafor C, Dixon P, Powell KC, Chauhan A. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. Adv Colloid Interface Sci. 2016 Jul;233:139–154. doi: 10.1016/j.cis.2015.08.002.Watson S., Lowe G. Ocular anatomy and physiology relevant to anaesthesia. Anaesth. Intensive Care Med. 2019;20:710–715. doi: 10.1016/j.mpaic.2019.10.004.Watson S., Lowe G. Ocular anatomy and physiology relevant to anaesthesia. Anaesth. Intensive Care Med. 2019;20:710–715. doi: 10.1016/j.mpaic.2019.10.004.Suri R., Beg S., Kohli K. Target strategies for drug delivery bypassing ocular barriers. J. Drug Deliv. Sci. Technol. 2020;55:101389. doi: 10.1016/j.jddst.2019.101389.Suri R., Beg S., Kohli K. Target strategies for drug delivery bypassing ocular barriers. J. Drug Deliv. Sci. Technol. 2020;55:101389. doi: 10.1016/j.jddst.2019.101389.Moiseev RV, Morrison PWJ, Steele F, Khutoryanskiy VV. Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics. 2019 Jul 9;11(7):321. doi: 10.3390/pharmaceutics11070321.Moiseev RV, Morrison PWJ, Steele F, Khutoryanskiy VV. Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics. 2019 Jul 9;11(7):321. doi: 10.3390/pharmaceutics11070321.Ramsay E, Del Amo EM, Toropainen E, Tengvall-Unadike U, Ranta VP, Urtti A, Ruponen M. Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci. 2018 Jul 1;119:83–89. doi: 10.1016/j.ejps.2018.03.034.Ramsay E, Del Amo EM, Toropainen E, Tengvall-Unadike U, Ranta VP, Urtti A, Ruponen M. Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci. 2018 Jul 1;119:83–89. doi: 10.1016/j.ejps.2018.03.034.Mofidfar M, Abdi B, Ahadian S, et al. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Int J Pharm. 2021;607:120924. doi: 10.1016/j.ijpharm.2021.120924.Mofidfar M, Abdi B, Ahadian S, et al. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Int J Pharm. 2021;607:120924. doi: 10.1016/j.ijpharm.2021.120924.Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M, Siegenthaler J, Xu L, Basile AS, Tang-Liu DD, Giacomini KM. Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm. 2013 Feb 4;10(2):650–663. doi: 10.1021/mp300429e.Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M, Siegenthaler J, Xu L, Basile AS, Tang-Liu DD, Giacomini KM. Gene expression profiling of trans porters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm. 2013 Feb 4;10(2):650–663. doi: 10.1021/mp300429e.Li H, Dai F, Liu H, Tao Q, Hu J, Zhang Y, Xiao Z, Rupenthal ID, Li H, Yang F, Li W, Lin H, Hou D. Physicochemical properties and micro-interaction between micronanoparticles and anterior corneal multilayer biological interface film for improving drug delivery efficacy: the transformation of tear film turnover mode. Drug Deliv. 2023 Dec;30(1):2184312. doi: 10.1080/10717544.2023.2184312.Li H, Dai F, Liu H, Tao Q, Hu J, Zhang Y, Xiao Z, Rupenthal ID, Li H, Yang F, Li W, Lin H, Hou D. Physicochemical properties and micro-interaction between micronanoparticles and anterior corneal multilayer biological interface film for improv ing drug delivery efficacy: the transformation of tear film turnover mode. Drug Deliv. 2023 Dec;30(1):2184312. doi: 10.1080/10717544.2023.2184312.Agarwal R, Iezhitsa I, Agarwal P, Abdul Nasir NA, Razali N, Alyautdin R, Ismail NM. Liposomes in topical ophthalmic drug delivery: an update. Drug Deliv. 2016 May;23(4):1075–1091. doi: 10.3109/10717544.2014.943336.Agarwal R, Iezhitsa I, Agarwal P, Abdul Nasir NA, Razali N, Alyautdin R, Is mail NM. Liposomes in topical ophthalmic drug delivery: an update. Drug Deliv. 2016 May;23(4):1075–1091. doi: 10.3109/10717544.2014.943336.Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM. Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther. 2013 Mar;29(2):92–105. doi: 10.1089/jop.2012.0241.Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM. Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther. 2013 Mar;29(2):92–105. doi: 10.1089/jop.2012.0241.Cova TF, Murtinho D, Pais AACC, Valente AJM. Combining Cellulose and Cyclodextrins: Fascinating Designs for Materials and Pharmaceutics. Front Chem. 2018;6:271. Published 2018 Jul 5. doi: 10.3389/fchem.2018.00271.Cova TF, Murtinho D, Pais AACC, Valente AJM. Combining Cellulose and Cyclodextrins: Fascinating Designs for Materials and Pharmaceutics. Front Chem. 2018;6:271. Published 2018 Jul 5. doi: 10.3389/fchem.2018.00271.Esteban-Pérez S., Andrés-Guerrero V., López-Cano J.J., Molina-Martínez I., Herrero-Vanrell R., Bravo-Osuna I. Gelatin nanoparticles-HPMC hybrid system for effective ocular topical administration of antihypertensive agents. Pharmaceutics. 2020;12:306. doi: 10.3390/pharmaceutics12040306.Esteban-Pérez S., Andrés-Guerrero V., López-Cano J.J., Molina-Martínez I., Herrero-Vanrell R., Bravo-Osuna I. Gelatin nanoparticles-HPMC hybrid system for effective ocular topical administration of antihypertensive agents. Pharmaceutics. 2020;12:306. doi: 10.3390/pharmaceutics12040306.Morrison PW, Connon CJ, Khutoryanskiy VV. Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability. Mol Pharm. 2013 Feb 4;10(2):756–762. doi: 10.1021/mp3005963.Morrison PW, Connon CJ, Khutoryanskiy VV. Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability. Mol Pharm. 2013 Feb 4;10(2):756–762. doi: 10.1021/mp3005963.Morrison PW, Khutoryanskiy VV. Enhancement in corneal permeability of riboflavin using calcium sequestering compounds. Int J Pharm. 2014;472(1–2):56–64. doi: 10.1016/j.ijpharm.2014.06.007.Morrison PW, Khutoryanskiy VV. Enhancement in corneal permeability of ribofla vin using calcium sequestering compounds. Int J Pharm. 2014;472(1–2):56–64. doi: 10.1016/j.ijpharm.2014.06.007.Morrison PWJ, Porfiryeva NN, Chahal S, Salakhov IA, Lacourt C, Semina II, Moustafine RI, Khutoryanskiy VV. Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery? Mol Pharm. 2017 Oct 2;14(10):3528–3538. doi: 10.1021/acs.molpharmaceut.7b00556.Morrison PWJ, Porfiryeva NN, Chahal S, Salakhov IA, Lacourt C, Semina II, Moustafine RI, Khutoryanskiy VV. Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery? Mol Pharm. 2017 Oct 2;14(10):3528–3538. doi: 10.1021/acs.molpharmaceut.7b00556.Stojančević M., Pavlović N., Goločorbin-Kon S., Mikov M. Application of bile acids in drug formulation and delivery. Front. Life Sci. 2013;7:112–122. doi: 10.1080/21553769.2013.879925.Stojančević M., Pavlović N., Goločorbin-Kon S., Mikov M. Application of bile acids in drug formulation and delivery. Front. Life Sci. 2013;7:112–122. doi: 10.1080/21553769.2013.879925.Pescina S, Ostacolo C, Gomez-Monterrey IM, Sala M, Bertamino A, Sonvico F, Padula C, Santi P, Bianchera A, Nicoli S. Cell penetrating peptides in ocular drug delivery: State of the art. J Control Release. 2018 Aug 28;284:84–102. doi: 10.1016/j.jconrel.2018.06.023. Epub 2018 Jun 18. PMID: 29913221Pescina S, Ostacolo C, Gomez-Monterrey IM, Sala M, Bertamino A, Sonvico F, Padula C, Santi P, Bianchera A, Nicoli S. Cell penetrating peptides in ocular drug delivery: State of the art. J Control Release. 2018 Aug 28;284:84–102. doi: 10.1016/j.jconrel.2018.06.023. Epub 2018 Jun 18. PMID: 29913221Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov. Today. 2008;13:144–151. doi: 10.1016/j.drudis.2007.10.021.Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov. Today. 2008;13:144–151. doi: 10.1016/j.drudis.2007.10.021.Antunes A., De Geest B., Vervaet C., Remon J. Gelucire 44/14 based immediate release formulations for poorly water-soluble drugs. Drug Dev. Ind. Pharm. 2012;39:791–798. doi: 10.3109/03639045.2012.709251.Antunes A., De Geest B., Vervaet C., Remon J. Gelucire 44/14 based immedi ate release formulations for poorly water-soluble drugs. Drug Dev. Ind. Pharm. 2012;39:791–798. doi: 10.3109/03639045.2012.709251.Tundisi LL, Mostaço GB, Carricondo PC, Petri DFS. Hydroxypropyl methylcellulose: Physicochemical properties and ocular drug delivery formulations. Eur J Pharm Sci. 2021 Apr 1;159:105736. doi: 10.1016/j.ejps.2021.105736.Tundisi LL, Mostaço GB, Carricondo PC, Petri DFS. Hydroxypropyl methylcel lulose: Physicochemical properties and ocular drug delivery formulations. Eur J Pharm Sci. 2021 Apr 1;159:105736. doi: 10.1016/j.ejps.2021.105736.Weng J, Fink MK, Sharma A. A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations. Int J Mol Sci. 2023;24(3):2758. Published 2023 Feb 1. doi: 10.3390/ijms24032758.Weng J, Fink MK, Sharma A. A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations. Int J Mol Sci. 2023;24(3):2758. Published 2023 Feb 1. doi: 10.3390/ ijms24032758.Rincón-Iglesias M., Lizundia E., Lanceros-Méndez S. Water-soluble cellulose derivatives as suitable matrices for multifunctional materials. Biomacromolecules. 2019;20:2786–2795. doi: 10.1021/acs.biomac.9b00574.Rincón-Iglesias M., Lizundia E., Lanceros-Méndez S. Water-soluble cellulose derivatives as suitable matrices for multifunctional materials. Biomacromolecules. 2019;20:2786–2795. doi: 10.1021/acs.biomac.9b00574.National Center for Biotechnology Information (NCBI) [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] — [cited 2023 Jul 31].https://www.ncbi.nlm.nih.gov/pmcNational Center for Biotechnology Information (NCBI) [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] — [cited 2023 Jul 31].https://www.ncbi.nlm.nih.gov/pmcKathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use. J Clin Med. 2021;10(6):1289. Published 2021 Mar 21. doi: 10.3390/jcm10061289.Kathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use. J Clin Med. 2021;10(6):1289. Published 2021 Mar 21. doi: 10.3390/jcm10061289.Safarzadeh M, Azizzadeh P, Akbarshahi P. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. J Optom. 2017;10(4):258–264. doi: 10.1016/j.optom.2016.11.002.Safarzadeh M, Azizzadeh P, Akbarshahi P. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. J Optom. 2017;10(4):258–264. doi: 10.1016/j.optom.2016.11.002.Rajendraprasad RM, Kwatra G, Batra N. Carboxymethyl Cellulose versus Hydroxypropyl Methylcellulose Tear Substitutes for Dry Eye Due to Computer Vision Syndrome: Comparison of Efficacy and Safety. Int J Appl Basic Med Res. 2021;11(1):4– 8. doi: 10.4103/ijabmr.IJABMR_399_20.Rajendraprasad RM, Kwatra G, Batra N. Carboxymethyl Cellulose versus Hydroxy propyl Methylcellulose Tear Substitutes for Dry Eye Due to Computer Vision Syn drome: Comparison of Efficacy and Safety. Int J Appl Basic Med Res. 2021;11(1):4– 8. doi: 10.4103/ijabmr.IJABMR_399_20.Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3 % Hydroxypropyl Methylcellulose/Dextran Versus 0.18 % Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study. J Ocul Pharmacol Ther. 2015;31(6):323–329. doi: 10.1089/jop.2014.0115.Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3 % Hy droxypropyl Methylcellulose/Dextran Versus 0.18 % Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study. J Ocul Pharmacol Ther. 2015;31(6):323–329. doi: 10.1089/jop.2014.0115.Maharana PK, Raghuwanshi S, Chauhan AK, Rai VG, Pattebahadur R. Comparison of the Efficacy of Carboxymethylcellulose 0.5 %, Hydroxypropyl-guar Containing Polyethylene Glycol 400/Propylene Glycol, and Hydroxypropyl Methyl Cellulose 0.3 % Tear Substitutes in Improving Ocular Surface Disease Index in Cases of Dry Eye. Middle East Afr J Ophthalmol. 2017;24(4):202–206. doi: 10.4103/meajo.MEAJO_165_15.Maharana PK, Raghuwanshi S, Chauhan AK, Rai VG, Pattebahadur R. Comparison of the Efficacy of Carboxymethylcellulose 0.5 %, Hydroxypropyl-guar Containing Polyethylene Glycol 400/Propylene Glycol, and Hydroxypropyl Methyl Cellulose 0.3 % Tear Substitutes in Improving Ocular Surface Disease Index in Cases of Dry Eye. Middle East Afr J Ophthalmol. 2017;24(4):202–206. doi: 10.4103/meajo.MEAJO_165_15.Prinz A, Fennes C, Buehl W, Findl O. Efficacy of ophthalmic viscosurgical devices in maintaining corneal epithelial hydration and clarity: in vitro assessment. J Cataract Refract Surg. 2012 Dec;38(12):2154–2159. doi: 10.1016/j.jcrs.2012.06.054.Prinz A, Fennes C, Buehl W, Findl O. Efficacy of ophthalmic viscosurgical devices in maintaining corneal epithelial hydration and clarity: in vitro assessment. J Cataract Refract Surg. 2012 Dec;38(12):2154–2159. doi: 10.1016/j.jcrs.2012.06.054.Yusufu M, Liu X, Zheng T, Fan F, Xu J, Luo Y. Hydroxypropyl methylcellulose 2 % for dry eye prevention during phacoemulsification in senile and diabetic patients. Int Ophthalmol. 2018 Jun;38(3):1261–1273. doi: 10.1007/s10792-017-0590-7.Yusufu M, Liu X, Zheng T, Fan F, Xu J, Luo Y. Hydroxypropyl methylcellulose 2 % for dry eye prevention during phacoemulsification in senile and diabetic patients. Int Ophthalmol. 2018 Jun;38(3):1261–1273. doi: 10.1007/s10792-017-0590-7.Wilkins MR, Khan S, Bunce C, Khawaja A, Siriwardena D, Larkin DF. A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis. Br J Ophthalmol. 2011 Sep;95(9):1299–1303. doi: 10.1136/bjo.2010.188623.Wilkins MR, Khan S, Bunce C, Khawaja A, Siriwardena D, Larkin DF. A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis. Br J Ophthalmol. 2011 Sep;95(9):1299–1303. doi: 10.1136/bjo.2010.188623.Махова МВ, Ших ЕВ, Страхов ВВ, Блинов ДС, Полуосьмак ГК, Семелева ЕВ, Блинова ЕВ. Клиническое и экспериментальное обоснование применения фенилэфрина с гипромеллозой в лечении перенапряжения аккомодации у пациентов с миопией. Клиническая офтальмология. 2023;23(1):33-38. DOI: 10.32364/2311-7729-2023-23-1-33-38Makhova MV, Shikh EV, Strakhov VV, Blinov DS, Poluosmak GK, Semeleva EV, Blinova EV. Clinical and experimental rationale for using phenylephrine with Hypromellose for the treatment of extra accommodation strain in patients with myopia. Russian Journal of Clinical Ophthalmology. 2023;23(1):33–38 (in Russ.). doi: 10.32364/2311-7729-2023-23-1-33-38.)Блинова ЕВ, Полуосьмак ГК, Литвин ЕА, Блинов ДС, Ших МВ, Вавилова ОС, Василькина ОВ, Ших ЕВ. Влияние гипромеллозы на динамику мидриатического эффекта фенилэфрина в эксперименте. Российский офтальмологический журнал. 2023;16(1):119-126.Blinova EV, Poluosmak GK, Litvin EA. et al. Hypromellose improves mydriasis dynamics by phenylephrine in a rabbit experimental model. Russian Ophthalmological Journal. 2023;16(1):119-126. doi: 10.21516/2072-0076-2023-16-1-119-126Sanap SN, Bisen AC, Kedar A, Yadav KS, Krishna A, Akhir A, Chopra S, Mugale MN, Bhatta RS. Chitosan/HPMC-based mucoadhesive film co-loaded with fluconazole and ofloxacin for management of polymicrobial keratitis. Int J Biol Macromol. 2022 Dec 1;222(Pt B):2785-2795. doi: 10.1016/j.ijbiomac.2022.10.058.Sanap SN, Bisen AC, Kedar A, Yadav KS, Krishna A, Akhir A, Chopra S, Mugale MN, Bhatta RS. Chitosan/HPMC-based mucoadhesive film co-loaded with fluconazole and ofloxacin for management of polymicrobial keratitis. Int J Biol Macromol. 2022 Dec 1;222(Pt B):2785-2795. doi: 10.1016/j.ijbiomac.2022.10.058.Long Y, Zhao X, Liu S, Chen M, Liu B, Ge J, Jia YG, Ren L. Collagen-Hydroxypropyl Methylcellulose Membranes for Corneal Regeneration. ACS Omega. 2018 Jan 31;3(1):1269-1275. doi: 10.1021/acsomega.7b01511.Long Y, Zhao X, Liu S, Chen M, Liu B, Ge J, Jia YG, Ren L. Collagen-Hydroxypro pyl Methylcellulose Membranes for Corneal Regeneration. ACS Omega. 2018 Jan 31;3(1):1269-1275. doi: 10.1021/acsomega.7b01511.de Silva DJ, Olver JM. Hydroxypropyl methylcellulose (HPMC) lubricant facilitates insertion of porous spherical orbital implants. Ophthalmic Plast Reconstr Surg. 2005 Jul;21(4):301-2. doi: 10.1097/01.iop.0000170417.19223.6cde Silva DJ, Olver JM. Hydroxypropyl methylcellulose (HPMC) lubricant facilitates insertion of porous spherical orbital implants. Ophthalmic Plast Reconstr Surg. 2005 Jul;21(4):301-2. doi: 10.1097/01.iop.0000170417.19223.6cContreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Orozco-Ceja V, Rodríguez-Herrera LY. Real-Life Active Surveillance of a Naphazoline/ Hypromellose Fixed Combination’s Safety Profile in Peruvian Population. Integr Pharm Res Pract. 2021;10:127–133. Published 2021 Oct 16. doi: 10.2147/IPRP.S332421.Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Orozco-Ceja V, Rodríguez-Herrera LY. Real-Life Active Surveillance of a Naphazoline/ Hypromel lose Fixed Combination’s Safety Profile in Peruvian Population. Integr Pharm Res Pract. 2021;10:127–133. Published 2021 Oct 16. doi: 10.2147/IPRP.S332421.Jeganathan B, Prakya V. Interpolyelectrolyte complexes of Eudragit® EPO with hypromellose acetate succinate and Eudragit® EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery. AAPS PharmSciTech. 2015;16(4):878–888. doi: 10.1208/s12249-014-0252-2.Jeganathan B, Prakya V. Interpolyelectrolyte complexes of Eudragit® EPO with hypromellose acetate succinate and Eudragit® EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery. AAPS PharmSciTech. 2015;16(4):878–888. doi: 10.1208/s12249-014-0252-2.Mašková E, Naiserová M, Kubová K, Mašek J, Pavloková S, Urbanová M, Brus J, Vysloužil J, Vetchý D. Highly Soluble Drugs Directly Granulated by Water Dispersions of Insoluble Eudragit® Polymers as a Part of Hypromellose K100M Matrix Systems. Biomed Res Int. 2019 Mar 5;2019:8043415. doi: 10.1155/2019/8043415.Mašková E, Naiserová M, Kubová K, Mašek J, Pavloková S, Urbanová M, Brus J, Vysloužil J, Vetchý D. Highly Soluble Drugs Directly Granulated by Water Disper sions of Insoluble Eudragit® Polymers as a Part of Hypromellose K100M Matrix Systems. Biomed Res Int. 2019 Mar 5;2019:8043415. doi: 10.1155/2019/8043415.Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physico-chemical Properties: Case Study-Hypromellose (HPMC). AAPS J. 2020;22(2):49. Published 2020 Feb 18. doi: 10.1208/s12248-019-0411-1.Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical Understand ing of Excipient Variability on Drug Apparent Solubility Based on Drug Physico chemical Properties: Case Study-Hypromellose (HPMC). AAPS J. 2020;22(2):49. Published 2020 Feb 18. doi: 10.1208/s12248-019-0411-1.Mašková E, Kubová K, Raimi-Abraham BT, Vllasaliu D, Vohlídalová E, Turánek J, Mašek J. Hypromellose — A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. J Control Release. 2020 Aug 10;324:695-727. doi: 10.1016/j.jconrel.2020.05.045.Mašková E, Kubová K, Raimi-Abraham BT, Vllasaliu D, Vohlídalová E, Turánek J, Mašek J. Hypromellose — A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. J Control Release. 2020 Aug 10;324:695-727. doi: 10.1016/j.jconrel.2020.05.045.Bentley K, Stanton RJ. Hydroxypropyl Methylcellulose-Based Nasal Sprays Effectively Inhibit In Vitro SARS-CoV-2 Infection and Spread. Viruses. 2021;13(12):2345. Published 2021 Nov 23. doi: 10.3390/v13122345.Bentley K, Stanton RJ. Hydroxypropyl Methylcellulose-Based Nasal Sprays Effec tively Inhibit In Vitro SARS-CoV-2 Infection and Spread. Viruses. 2021;13(12):2345. Published 2021 Nov 23. doi: 10.3390/v13122345.Shmuel K, Dalia M, Tair L, Yaakov N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti Infect Ther. 2021;19(10):1325–1330. doi: 10.1080/14787210.2021.1908127.Shmuel K, Dalia M, Tair L, Yaakov N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti Infect Ther. 2021;19(10):1325–1330. doi: 10.1080/14787210.2021.1908127.Yadavalli T, Mallick S, Patel P, Koganti R, Shukla D, Date AA. Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs. ACS Infect Dis. 2020;6(11):2926–2937.Yadavalli T, Mallick S, Patel P, Koganti R, Shukla D, Date AA. Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs. ACS Infect Dis. 2020;6(11):2926–2937.Siegel DT, Hubbard GB, Yan J, Cribbs B, Jain N, Yeh S, Bui D, Smith J, Barb S, Pearce W, Ward L, Hendrick AM. EFFECT OF LUBRICANTS ON CORNEAL THICKNESS AFTER VITRECTOMY. Retina. 2020 Aug;40(8):1616-1622. doi: 10.1097/IAE.0000000000002639.Siegel DT, Hubbard GB, Yan J, Cribbs B, Jain N, Yeh S, Bui D, Smith J, Barb S, Pearce W, Ward L, Hendrick AM. EFFECT OF LUBRICANTS ON CORNEAL THICKNESS AFTER VITRECTOMY. Retina. 2020 Aug;40(8):1616-1622. doi: 10.1097/ IAE.0000000000002639.Tonjum AM. Effects of benzalkonium chloride upon the corneal epithelium studied with scanning eletron microscopy. Acta Ophthalmol. 2009;53(3):358–366.Tonjum AM. Effects of benzalkonium chloride upon the corneal epithelium studied with scanning eletron microscopy. Acta Ophthalmol. 2009;53(3):358–366.

The authors declare that there are no conflicts of interest present.